Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29428975 | 0.98 | SLC6A3 (0.66) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL1672596 | 0.86 | SLC6A3 (0.81) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL12542428 | 0.86 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2P2RX7LMNA | |
| SCHEMBL2562611 | 0.82 | SLC6A3 (0.89) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL5495766 | 0.82 | SLC6A3 (0.96) | SLC6A3SLC6A4DPP4SLC6A2 | |
| SCHEMBL2701343 | 0.81 | SLC6A3 (0.68) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL12614285 | 0.81 | SLC6A3 (0.45) | SLC6A3SLC6A4SLC6A2P2RX7ICMT | |
| SCHEMBL3416399 | 0.81 | LMNA (0.48) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL1492948 | 0.81 | MAOA (0.73) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL3518807 | 0.81 | SLC6A3 (1.00) | SLC6A3SLC6A4DPP4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | SLC6A3 3169/4885SLC6A4 2532/4885MAOA 2507/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | SLC6A3 3169/4885SLC6A4 2532/4885MAOA 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.